DOI: 10.36347/sajp.2021.v10i10.002

Pages: 163-176

Background: Anemia management is complicated in patients with End Stage Renal Disease (ESRD) on hemodialysis. Clinical pharmacists have been involved in the care of ESRD patients in various settings. Aims of the study: The aim of this study was to explore the therapeutic and pharmacoeconomic outcome of a clinical pharmacist- implemented anemia management in dialysis patients through a randomized, controlled, open label design clinical study. Methods: The study was carried out over a period of three months at renal /hemodialysis unit of King Hussein Medical Center at the Royal Medical Services. A total 203 patients of both genders on hemodialysis were randomized into an intervention or control arm, 102 patients were allocated to the intervention arm and 101 patients to the control arm. In the intervention arm, patients received physician-pharmacist collaborative care. In the control arm, patients received usual care. Results: In this study, clinical pharmacist interventions had a positive impact on achieving target goal of Hb concentrations among HD patients. The percent of patients who achieved target Hb and Hct at the end of the study was 87.2% in the intervention arm versus 36.6% in the control arm, p = 0.02). Patients in the intervention arm used less epoetin α, leading to a savings of 5723.4 JD. The average amount of epoetin α vials used in the intervention arm was significantly lower than that in the control arm (p = 0.002). Conclusion: Clinical pharmacists can positively contribute to the care of ESRD patients and reduce the gaps in current patient care.